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Abstract
Background: Leishmaniasis is a virulent parasitic infection that causes a worldwide disease burden. Most
treatments have toxic side-effects and efficacy has decreased due to the emergence of resistant strains. The
outlook is worsened by the absence of promising drug targets for this disease. We have taken a computational
approach to the detection of new drug targets, which may become an effective strategy for the discovery of new
drugs for this tropical disease.
Results: We have predicted the protein interaction network of Leishmania major by using three validated methods:
PSIMAP, PEIMAP, and iPfam. Combining the results from these methods, we calculated a high confidence network
(confidence score > 0.70) with 1,366 nodes and 33,861 interactions. We were able to predict the biological process
for 263 interacting proteins by doing enrichment analysis of the clusters detected. Analyzing the topology of the
network with metrics such as connectivity and betweenness centrality, we detected 142 potential drug targets
after homology filtering with the human proteome. Further experiments can be done to validate these targets.
Conclusion: We have constructed the first protein interaction network of the Leishmania major parasite by using a
computational approach. The topological analysis of the protein network enabled us to identify a set of candidate
proteins that may be both (1) essential for parasite survival and (2) without human orthologs. These potential
targets are promising for further experimental validation. This strategy, if validated, may augment established drug
discovery methodologies, for this and possibly other tropical diseases, with a relatively low additional investment of
time and resources.
Background
Leishmaniasis is a complex infectious disease caused by
several species of the Leishmania genus, affecting more
than 2 million of people around the world in 88 coun-
tries. In addition to endemic countries, there have been
increasing numbers of cases in non-endemic countries
due to tourism [1-5]. The parasite is transmitted to
human or animal reservoirs by the female insect of the
genus Lutzomyia in the New World and Phlebotomus in
the Old World [1]. Leishmaniasis has three main clinical
presentations: cutaneous, mucocutaneous and visceral.
The visceral form affects mainly children, who can die if
adequate treatment is not provided in a timely manner.
The cutaneous and mucocutaneous forms can cause
severe disabilities in adults, affecting productivity in
rural areas. At present, there are no available vaccines
for this disease in spite of multiple research efforts [6].
The main measures for controlling the disease rely upon
chemotherapy and vector control, which are tightly
related given that human beings may act as reservoirs
for the parasites in some endemic areas (antropozoono-
tic transmission). In spite of these measures, the number
of cases continue to increase in many endemic coun-
tries, such as Colombia [7].
Current anti-leishmanial therapy has been unsuccess-
ful due to toxicity, varying sensitivity of different Leish-
mania species, diversity of host immune responses, and
different pharmacokinetics of the drug employed. The
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classical treatment for all forms of leishmaniasis has
been pentavalent antimony in the form of sodium stibo-
gluconate (Pentostam, Glaxo-Smith-Kline) or meglu-
mine antimoniate (Glucantime, Rhone-Polenc). Severe
side effects, including death, are associated with these
compounds [8,9], and increasing resistance to antimo-
nials is currently a major problem in many endemic
countries [2,10]. Several drugs, such as Pentamidine and
Amphotericin B, have also been used for leishmaniasis
treatment. However, the presence of side effects, route
of administration (injection rather than a pill), high cost,
and differences in efficacy against the different clinical
forms of the disease constrain their widespread use as
drugs of choice. More recently, Miltefosine, an oral
drug, originally developed as an antineoplastic com-
pound, has been used successfully for treatment of visc-
eral and cutaneous leishmaniasis [11,12], but with
variable efficacy in Central and South America [13].
Moreover, a phase IV trial in India has shown an incre-
ment in the relapse rate with Miltefosine, indicating that
drug resistance may develop quickly [14,15]. For all
these reasons, there is an urgent need for new, safe, and
cheap anti-leishmanial compounds.
Drug discovery efforts, through public private partner-
ships, for the primary protozoal parasitic diseases of the
developing world –malaria, leishmaniasis, and trypano-
somiasis – have renewed the interest in developing new
drugs and vaccines that can be accessible to the affected,
primarily poor, population [16]. The drug discovery pro-
cess begins with a search for drug targets that must ful-
fill two main requirements in the case of infectious
diseases; (1) to be essential for the parasite survival and
(2) to be specific, in that the target should not have a
counterpart in the human host that can give rise to
toxic effects. However, there is no consensus yet on the
best biological indicators of essentiality. Indicators such
as expression level and subcellular localization have
been used to classify proteins as druggable. However,
these assumptions often do not account for the com-
plexity of the underlying biological network of interac-
tions among those proteins [17].
New research initiatives have been undertaken to col-
lect genome sequences along with high-throughput
expression and proteomic data from different organisms.
This constitutes an important source of biological infor-
mation that can be employed efficiently in the search
for new drugs for a large number of human and veterin-
ary diseases. Bioinformatics tools have enabled research-
ers to extract and manipulate this biological information
with the goal of understanding protein function. Unfor-
tunately, the knowledge of the functions of proteins in
their native form has not yet provided us with an under-
standing of the complexity of cellular behavior, thus
there is not yet a clear definition of essentiality. Proteins
inside the cell typically do not function in their native
state alone, but rather by interacting in concert with
other proteins, generating a high dimensional network
with a complicated structure. Because of the networked
nature of protein function, topological analysis of the
protein network may help to identify essential proteins
that can be potentially drug or vaccine targets. Recent
studies carried out with experimental protein interaction
networks of Saccharomyces cerevissiae and Caenorhabdi-
tis elegans, [18,19] have confirmed the effectiveness of
topological metrics in predicting protein essentiality,
demonstrating strong correlation with knockout and
knockdown data. These studies have also expanded to
organisms of medical importance, such as the protozoan
parasite Plasmodium falciparum [20], in the interest of
discovering new drug and vaccine targets. This data is
available through the system PlasmoID [21]. Topological
analysis has also been useful in detecting important pro-
teins, even when the protein network has been predicted
using an orthology-based method, as in the case of the
human interactome [22].
In this work, we predicted the protein network of
Leishmania major using protein sequences via three
methods, iPfam, PSIMAP and PEIMAP. We analyzed
the predicted protein network with the metrics of con-
nectivity and betweenness centrality, in order to identify
essential proteins. Protein interaction data were analyzed
to detect GO enriched clusters, to determine the possi-
ble pathways of detected targets, and to infer the biolo-
gical processes performed by proteins with unknown
functional description. The list of putative protein tar-
gets is a starting point for experimental validation by
in vitro assays and further discovery of new anti-leish-
manial drugs.
Methods
Protein network prediction using PSIMAP, iPfam and
PEIMAP
Predictions of protein-protein interactions (PPIs) were
generated using the pipeline previously designed and
applied in Xanthomonas oryzae [23], employing three
different methods: PSIMAP, iPfam, and PEIMAP.
PSIMAP
PSIMAP http://psimap.com/ [24] infers interactions
between proteins by using interacting domain pairs from
known PDB (Protein Data Bank) structures. We extracted
protein sequences of Leishmania major from the GeneDB
database ftp://ftp.sanger.ac.uk/pub/databases/L.major_se-
quences/DATASETS/LmjFwholegenome_20070731_V5.2.
pep. We aligned these sequences using PSI-BLAST [25]
against the SCOP 1.71 database [26] with an E-value cutoff
of 0.0001, as described previously in [23]. We predicted a
total of 158,984 interactions for 3,184 proteins by applying
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PSIMAP [27] domain pairs to the domain assignment.
The original definition of interaction in this database is
based on atomic distance between domains in the
structures of protein complexes.
iPfam
We analyzed iPfam interactions using domain assign-
ments from Pfam release 18.0 [28] using the tool
hmmpfam with an E-value cutoff of 0.01. By integrating
them with Pfam domain interaction pairs from iPfam
[29], a total of 50,398 predicted protein-protein interac-
tions were constructed from 2,336 Leishmania proteins.
PEIMAP
We aligned Leishmania proteins with the PEIMAP data-
base http://peimap.kobic.re.kr using BLASTP [25] with a
minimal cutoff of 40% sequence identity and 70% length
coverage. The PEIMAP database includes protein-pro-
tein interaction (PPI) information from six source data-
bases: DIP, [30] BIND, [31] IntAct, [32] MINT, [33]
HPRD, [34] and BioGrid [35]. A total of 14,839 interac-
tions were extracted involving 718 Leishmania proteins.
Selecting confident predicted protein interactions
We used the ‘combined score’ method, applied in [23]
and also used in the STRING database [36]. This
method takes into account the reliability of each method
(PEIMAP, PSIMAP and iPfam), assuming independence
among them. The score is calculated according to the
formula:
score Ri
n
i E
= − −
∈
∏1 1( )
Where score is the confidence score, E is the set of
methods under analysis (PEIMAP, PSIMAP, iPfam); Ri
is the reliability of method i, n is the number of interac-
tions predicted by method i. The reliability score of PEI-
MAP comes from previous reported data [37] that takes
into account the reliability of each experimental method
for detecting protein interactions. The reliability score
of iPfam is extracted from the score between two Pfam
domains from iPfam database. Finally, the reliability
score of PSIMAP uses the calculated distance between
interacting structural domains (SCOP).
The final score was further normalized to the range of
0.0 to 1.0 combining all the scores. We selected 1,366
Leishmania proteins participating in 33,861 high-confi-
dence PPIs, (confidence score >0.7), combining the
results from the three methods employed (Additional
file 1: Cytoscape network of Leishmania interactome).
To evaluate the confidence of the metric results, the
clustering coefficient and mean shortest path were com-
pared against 1,000 random networks generated with
the Random Network Plugin in Cytoscape [38], and
empirical p-values were computed.
Detection of essential proteins with topological metrics
and homology filtering with human proteome
Power law fit for the protein network was calculated
using Network Analyzer v.2.6.1 [39]. Network topology
metrics, such as betweenness centrality, connectivity,
and the Double Scoring Scheme (DSS) were used to
detect essential genes, using the Hubba server http://
hub.iis.sinica.edu.tw/Hubba. This method takes into
account weighted edges (confidence scores). The calcu-
lations were done over the largest component of the
network, with 0.7 confidence cutoff. This cutoff was
chosen to better fit the data with a power law distribu-
tion of the network. The detected targets were filtered
by discarding Leishmania orthologs to human proteins.
Clustering and GO enrichment analysis
We conducted cluster analysis of the largest component
in the network in order to detect protein complexes and
pathways. We used the Markov Clustering (MCL) algo-
rithm [40,41], which has been demonstrated as a robust
and fast algorithm to detect clusters in protein networks
[42], using the implementation in the NeAT tool [43].
For proteins of unknown function in the GeneDB data-
base http://www.genedb.org/Homepage/Lmajor, we pre-
dicted their possible biological roles by evaluating the
results of GO enrichment analysis, using the BinGO
plugin for Cytoscape.
Results and Discussion
We constructed a protein-protein interaction (PPI) map,
combining the results generated by PEIMAP, iPfam and
PSIMAP. Despite the absence of protein interaction data
for Leishmania major and the fact that protein interac-
tion data from single organisms may contain some false
positives that can bias the results, the use of interaction
data from different species can help to reduce the noise
in the predicted network [44]. Comparison to random
networks and utilization of experimental evidence that
confirms the essentiality of some of the predicted targets
are indirect ways of validating the calculated PPI map.
Other studies have successfully applied this approach to
discovering drug targets using computational methods
to predict protein networks, e.g. blast rice fungus,
M. tuberculosis, and Homo sapiens [45-47]. The pre-
dicted Leishmania major interactome can be a starting
point for future experimental PPI maps in Leishmania,
particularly given the fact that many interactions may
require post-translational modifications that may not
occur in yeast [48], thus making it difficult to perform
yeast-two-hybrid assays in this organism. The entire pre-
dicted network comprises 3,991 nodes and 190,708
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interactions (including self loops and duplicate edges).
The reduced coverage is likely due to the inability to
perform domain assignment to several proteins in Leish-
mania. Only 18.0% of the Leishmania proteome is con-
served across species (as defined in the CluSTr database:
http://www.ebi.ac.uk/integr8/ClustrAnalysisPageOnly.do?
orgProteomeID = 21780). This is a common limitation
of orthology-based methods for protein network
prediction.
It has been proposed that biological networks follow
a power law distribution that corresponds to scale-free
topology [49]. This is a global property of biological
networks and it is important for a reliable prediction
of essentiality when the metrics of connectivity and
betweenness centrality are used. We performed the fit-
ting of the node degree distribution to a power law
using the least squares method, to determine if our
predicted network was consistent with scale free topol-
ogy. This resulted in an exponent of -0.867 (R2= 0.556)
for the 0.60 confidence network. However, the calcu-
lated distribution for the 0.70 of confidence network
showed an appreciable increase of the R2 coefficient to
0.758 and the exponent to -1.199. This result does not
correlate well with power law distribution, possibly
because subnetworks can have a different degree of
distribution compared to the entire interactome. More-
over, it has been pointed out that geometric models
could fit better than power law distribution [50,51]. In
spite of these limitations, we chose the 0.70 confidence
cutoff, given that the network generated by applying
this cuttoff fits better with a scale-free topology. This
also enabled us to claim with more confidence that a
detected hub and bottleneck node may be essential for
the network.
Indentifying putative drug targets
Once the power law distribution is partially confirmed,
other topological characteristics can be biologically
meaningful. With this in mind, we conducted local
topology analysis to identify hubs and bottlenecks that
could be putative drug targets. We calculated connectiv-
ity and betweenness centrality over the 1,366-node net-
work with 33,861 interactions (>0.70 confidence). For all
of these calculations we used the largest component and
excluded isolated components from the larger original
network, mainly because betweenness centrality, which
calculates the number of shortest paths through a parti-
cular node, may generate an infinite number of shortest
paths from isolated nodes, which can become confusing
and make interpretation more difficult. The clustering
coefficient and the mean shortest path of the network
were compared against 1,000 random networks, (Table
1). We found that our protein network is more highly
connected when its clustering coefficient is compared
against the clustering coefficient values of the randomly
generated networks. These results suggest that our net-
work exhibits a modular architecture like other biologi-
cal networks. This makes us more confident that the
clusters might correlate with biological pathways. The
mean shortest path is also significantly different from
that of the random networks.
It has been shown that measures of connectivity [52]
and betweenness centrality [53] improve the identifica-
tion of essential proteins in protein networks [54].
Betweenness centrality correlates more closely with
essentiality than connectivity, exposing critical nodes
that usually belong to the group of scaffold proteins or
proteins involved in crosstalk between signalling path-
ways (called bottlenecks). This metric has also been pro-
posed in the new paradigm of network pharmacology as
a good feature for investigating potential drug targets
[55]. In the Leishmania major network, we selected the
top 10% of the connectivity ranking as hub nodes and
20% of the betweenness centrality ranking for bottle-
necks, according to previous methods for selecting such
cutoffs [54,56]. In addition, a recently developed tool,
HUBBA [57], provides an alternative way of prediction
of essential nodes by the combination of two metrics:
DMNC (Density of Maximum Neighborhood Compo-
nent) and MNC (Maximum Neighborhood Component).
Together, they are referred to as the Double Scoring
Scheme (DSS). We applied the DSS system to our high
confidence network with the goal of extending the range
of potential drug targets. We chose the cutoff of the top
10 proteins identified by this tool, because that cutoff
identifies the group with the highest probability to be
essential (close to 100%). However, we found that this
group overlaps with the group of detected hubs.
In this first detection, which combines the results
from connectivity, betweenness centrality, and DSS, we
identified 384 potential targets, shown in Additional
file 2: table S1. Once detected, targets need to be
checked for orthologs in the human proteome, given
that some drugs that bind conserved sites would per-
turb the corresponding human protein with possible
toxic consequences. Utilizing the list of Leishmania
orthologs to human proteins from the TDR database,
we filtered the list of targets, removing those with
homology to human proteins. The ortholog detection
in the TDR database was performed using the
OrthoMCL algorithm, which has shown high sensitiv-
ity compared to other methods [58], feature that it is
critical to identify all of the possible human orthologs
of Leishmania proteins. Once the Leishmania-human
ortholog proteins were ruled out, the total number of
potential proteins targets was reduced to 142 (Addi-
tional file 3: table S2). The network visualization of the
targets is shown in Figure 1.
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Gene Ontology enrichment analysis and function
prediction
It has been shown that detecting modular structures
inside a biological network provides insights into the
functional organization of cellular processes in living
organisms [59]. In addition, it has been recognized that
cluster detection combined with functional enrichment
analysis enables the prediction of the biological function
of proteins associated with a cluster [60]. We applied
the MCL algorithm to generate clusters in the network,
setting an inflation value of 1.8 and considering edge
weights (confidence scores) for the calculations. Func-
tional enrichment was carried out using BinGO, import-
ing the Leishmania major annotation from Gene
Ontology (GO) http://geneontology.org. We generated
63 clusters for the network. For each of those clusters,
we assigned the most significant GO biological process.
These results are shown in Additional file 4: table S3.
Close neighbours in protein interaction networks are
frequently involved in similar processes and it has been
shown that 70-80% of proteins in a cluster share at least
one function. This implies that any unclassified protein
could be tentatively assigned the function of its neigh-
bours [60,61]. We found that 263 proteins without
functional description in the GeneDB database are
related to well-defined clusters. We assigned a biological
process to those proteins based on the probability of
membership in a specific GO enriched cluster. By this
method, we predicted new protein roles for Leishmania
major that were previously unknown using current
annotation procedures (Additional file 5: table S4).
The largest cluster contains 15% of the proteins in the
network. They participate mainly in protein amino acid
phosphorylation (GO:0006468) (p-value < 0.00001).
Within the group of detected targets with no human
counterpart, we found that 64% of the targets were also
enriched in the protein amino acid phosphorylation pro-
cess (Figure 2, Additional file 6: table S5), followed by pro-
teins involved in nucleosome assembly (GO:0006334) 8%,
nucleic acid metabolic process (GO:0006139) 4%, electron
transport (GO:0006118) 4%, transport (GO:0006810) 4%,
and protein amino acid alkylation (GO:0006139) 2%. The
remaining proteins were distributed across processes with
one protein per process and classified as ‘other’; these
accounted for 14% of the target proteins. This analysis
suggests phosphoproteins as the main group to character-
ize and explore as drug targets. Proteins involved in
nucleic acid metabolism also should be explored as possi-
ble drug targets, given that Leishmania does not have the
enzymatic machinery to synthesize purines de novo [62].
Interestingly, proteins associated with nucleosome assem-
bly appear as alternative options.
Experimental evidence of the essentiality of predicted
targets
As mentioned above, there is a significant proportion of
phosphoproteins in the group of essential genes. This is
plausible, given that these proteins are important regula-
tors of differentiation and cell proliferation in many
eukaryotes. However, it has been pointed out that the
Leishmania kinome has particular distinctions from other
eukaryotic kinomes (for a good review see reference
[63]). We identified 91 kinases that were predicted as
essential proteins in the network with no homology to
the human kinome. This is an interesting and new group
of potential targets for future drug screening in this
organism, perhaps by using transfectant parasites as in
the methodology developed by our group [64]. Within
this group of kinases, LMPK [GeneDB:LmjF36.6470] has
been experimentally shown as essential in Leishmania
mexicana [65] with orthologs in L. amazonensis, L.
Table 1 Comparison of topology metrics of the predicted network versus random networks
Metric Predicted Network Random Networks Empirical P-value
Clustering Coefficient Average 0.70 0.18 ± 0.003 <0.001
Mean Shortest Path Average 3.91 2.42 ± 0.003 <0.001
The predicted network shows significant differences when compared to 1000 generated random networks preserving the node degree.
Figure 1 Cytoscape network for the Leishmania major
interactome. The nodes highlighted in red are predicted essential
nodes without human orthologs.
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major, L. tropica, L. aethiopica, L. donovani, L. infantum,
and L. braziliensis [66]. There is a growing interest in
this protein as a drug and vaccine candidate, given its
importance in parasite proliferation at the amastigote
stage.
A previous study has reconstructed the metabolic net-
work of Leishmania major from literature and carried
out flux balance analysis to predict potential drug tar-
gets [62]. However, when we compared the list of single
predicted knockouts found by modelling with the list
targets derived using topological methods, we did not
find any overlap. This could be due to the fact that
metabolic networks connect proteins by the metabolites
that they catalyze and not by direct interaction. How-
ever, when we analyzed the double knockouts list, we
found that the protein [GeneDB:LmjF36.1360] adenylate
kinase, was predicted to be essential in our network and
was also present in the double knockout pair of the
metabolic network [GeneDB:LmjF36.1360,LmjF25.2370].
This is highlighted in red on Figure 3. This implies that
redundancy in metabolic networks can also be detected
by computing betweenness centrality in protein net-
works. Inhibition of this protein caused low growth in
L. donovani promastigotes [67] and homology searching
identified orthologs in L.braziliensis, L.infantum, T. bru-
cei, and T. cruzi,. This would be advantageous in devel-
oping a drug for a wide spectrum of tropical diseases.
Additionally, a DrugBank http://www.drugbank.ca
search showed that the drug Gemcitabine could also
have an inhibitory effect upon this protein, illustrating
the potential use of this drug for tropical diseases
besides its current use in cancer.
[GeneDB:LmjF35.1180 and GeneDB:LmjF35.0830] are
fumarate reductase and fumarate reductase-like proteins
that have been predicted as essential in our network.
Neither has a human ortholog. Some reports have shown
that compounds such as chalcones [68] and aurones [69]
have a very potent inhibitory effect on these enzymes,
making them interesting compounds for future drug
development.
Three ABC transporters that were Leishmania specific
- [GeneDB:LmjF34.0670, GeneDB:LmjF27.0470, Gen-
eDB:LmjF32.2060] - were also predicted as essential.
They confer resistance to antimonials and pentamidine
by extruding the drug outside of the cell. Some research
groups are investigating inhibitors for this family of
transporters [70], with the goal of reverting the resistant
phenotype to a susceptible phenotype. Based upon our
analysis, we also identify these proteins as putative drug
targets because of their essential role in the homeostasis
of the parasite intracellular environment.
A final example that corroborates our findings with
experimental data is the detection of sterol 24-c-
methyltransferases [GeneDB:LmjF36.2390, GeneDB:
LmjF36.2380] as essential and exclusive in our net-
work. Those enzymes are involved in biosynthesis of
ergosterol, which is a target pathway in Leishmania
and fungi given its exclusivity and essentiality. Also, a
Figure 2 Correspondence between topological analysis and flux balance analysis. Partial representation of the Leishmania major
interactome. Red nodes represent the double knockout predictions from the Leishmania metabolic network. The node LmjF36.1360 was present
in the double knockout pair and also predicted as essential in the protein network. Betweenness centrality enables checking for redundancy.
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recent study identified methyl-transferase as a promis-
ing drug target in Cryptococcus neoformans [71]. More-
over, this enzyme has been recently tested as an
effective vaccine candidate in visceral leishmaniasis [72].
Finally, we looked at the expression level of exclusive
predicted targets in the microarray data reported by
Leifso et al., [73], and we did not find any significant
overexpression of the predicted essential genes at the
amastigote stage. This could be expected, given that few
genes have been found to be up or down-regulated across
promastigote and amastigote stages. This suggests that
essentiality could not be related to gene expression in the
case of Leishmania, given regulation of protein abun-
dance probably occurs at post-transcriptional level [73].
Conclusion
This work constitutes the first attempt to explore pro-
tein interaction networks in the Leishmania major para-
site by utilizing in silico methods. We have provided a
putative list of essential proteins; some of them backed
experimental evidence reported in literature. Of special
interest are the predicted essential kinases that consti-
tute an important group of Leishmania proteins to be
explored as sources of new drug targets, given that they
are important for parasite survival while having no
homology to the human kinome. Further experimental
studies are required to identify specific inhibitors. These
results will aid future drug discovery efforts for this dis-
ease, enabling drug development in a more timely and
cost-effective manner.
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Additional file 1: Cytoscape network of Leishmania interactome.
Leishmania major interactome in Cytoscape format with the annotation
and topological metrics as Cytoscape attributes.
Additional file 2: Table S1: List of targets detected by connectivity
and betweenness centrality but not filtered for human homology.
Additional file 3: Table S2: Final list of targets, excluding those with
human orthologs from table S1.
Additional file 4: Table S3: Clusters IDs from the whole network
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Additional file 5: Table S4: List of hypothetical proteins with
predicted biological process derived from the clustering and
enrichment analysis.
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